GLP-1 maintenance dosing claims: what the evidence supports

What did @mariahhopkins_ actually say?

This video is a provider recommendation, not a medical tutorial. @mariahhopkins_ tells viewers she has used the same GLP-1 provider for two years and lists what she sees as selling points: no membership fees, no cancellation fees, no BMI requirements, flat pricing regardless of dose, support for microdosing and maintenance, access to a dietitian, and an online portal. She invites followers to comment for her referral code.

There are no specific drug names mentioned, no dosing instructions, and no disease cure claims. The content is essentially a testimonial and affiliate promotion wrapped in community language. That framing matters when evaluating what she actually got right versus what deserves more scrutiny.

Does the science back this up?

The general concepts she references, including microdosing and maintenance dosing, do have real clinical grounding, though the evidence is more complicated than a TikTok caption suggests.

The idea of using lower GLP-1 doses for weight maintenance rather than active loss is gaining traction. A 2022 NEJM paper by Wilding et al. (the STEP 1 trial extension) found that patients who discontinued semaglutide regained roughly two-thirds of their prior weight loss within a year, which supports the argument for ongoing, possibly lower-dose use rather than stopping cold. Separately, a 2024 paper by Aronne et al. in Obesity examined titration flexibility and found that individualized dosing, including doses below standard maximum, could sustain meaningful outcomes in some patients.

No BMI requirement is a more contested point scientifically. Current FDA labeling for semaglutide 2.4mg (Wegovy) specifies BMI thresholds of 27 or 30 depending on comorbidity status. Providers can legally prescribe off-label without those thresholds, but that is a clinical judgment call, not a universal standard of care.

What did they get wrong (or right)?

She got the consumer transparency mostly right. Flat pricing, no hidden fees, and access to a dietitian are legitimate care access features worth naming, especially for people whose insurance dropped GLP-1 coverage, which has happened broadly as plans tightened formularies in 2023 and 2024.

Where the video is weaker is in how it frames "no BMI requirements" as simply "great for someone that might be in maintenance." That is true in some contexts, but it glosses over real clinical questions. Prescribing GLP-1 medications to people already at goal weight or with low BMI is genuinely off-label territory, and the long-term safety data in that population is thin. A 2023 review in The Lancet Diabetes and Endocrinology by Rubino et al. noted that evidence for GLP-1 use in weight maintenance specifically, as opposed to active loss, remains limited and that more trials are needed.

The microdosing framing also deserves scrutiny. It is not a formally studied protocol in any major RCT. Anecdotal success exists, but calling it a clinical feature of a provider is a marketing claim, not a medical one.

What should you actually know?

If you are shopping for a GLP-1 provider after losing insurance coverage, the practical checklist she describes, including no hidden fees, dietitian access, and flexible dosing conversations, reflects real things worth asking about. Those are fair consumer criteria.

However, "no BMI requirements" should be a prompt to ask more questions, not a reassurance. Any provider prescribing these medications should be doing a real clinical assessment of your individual risk-benefit profile, not simply removing a barrier. GLP-1 medications carry side effects including nausea, vomiting, gastroparesis risk, and potential thyroid concerns flagged in prescribing information. Those risks do not disappear because a BMI cutoff does.

Also worth noting: this video includes a referral code. That is a financial relationship. It does not make her experience invalid, but it means her recommendation is not purely disinterested. The FTC requires disclosure of material connections in sponsored content, and the disclosure here is implicit at best.

• Ask any telehealth provider what clinical criteria they use to determine candidacy, not just what requirements they have removed.
• Confirm whether you would be receiving a brand-name or compounded GLP-1 product, as these are not equivalent under FDA standards.
• Request that a licensed clinician, not just a portal, reviews your health history before any prescription is issued.